Literature DB >> 1317738

Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non-peptide antagonist.

F Feth1, W Rascher, M C Michel.   

Abstract

1. We have compared the binding and Ca2+ mobilizing properties of various full agonists, partial agonists and a non-peptide antagonist at the neuropeptide Y (NPY) receptor of human erythroleukemia (HEL) cells. 2. [125I]-NPY binding to intact HEL cells was rapid, saturable, of high affinity and with a specificity typical for the Y1-like subtype: NPY, peptide YY (PYY) and [Pro34]-NPY competed for [125I]-NPY binding with high affinity whereas NPY13-36 and NPY18-36 had only low affinity. 3. NPY, PYY and [Pro34]-NPY potently increased intracellular Ca2+ in HEL cells and had equal efficacy. NPY13-36, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP) increased intracellular Ca2+ only poorly. 4. Whereas VIP and PP did not significantly affect NPY-stimulated Ca2+ mobilization, NPY13-36 inhibited NPY-stimulated Ca2+ increases and shifted the NPY concentration-response curve to the right without altering its maximal effect. 5. The agonist (pEC50) potencies of the various peptides corresponded well with the affinities of these compounds in the binding assay (pKi), whereas the antagonist potencies (pKb) of the peptide partial agonists and the pA2 value of the non-peptide NPY antagonist (He 90481), calculated from functional data, were lower than the respective affinities determined in the binding studies. 6. A plot of the fractional Ca2+ response vs the fractional receptor occupancy did not reveal any non-linear receptor-effector coupling for NPY or [Pro34]-NPY; a small receptor reserve might exist for PYY. 7. We conclude that the binding and functional properties of HEL cell NPY receptors are very similar. NPY, PYY and [Pro34]NPY are full agonists at these receptors, whereas NPY13-36 is a partial agonist.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317738      PMCID: PMC1908622          DOI: 10.1111/j.1476-5381.1992.tb14212.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Neuropeptide Y and its receptor antagonists. Use of an analog mixture-screening strategy.

Authors:  K Tatemoto
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Specific [3H]propionyl-neuropeptide Y (NPY) binding in rabbit aortic membranes: comparisons with binding in rat brain and biological responses in rat vas deferens.

Authors:  R S Chang; V J Lotti; T B Chen
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

Review 3.  Receptors for neuropeptide Y: multiple subtypes and multiple second messengers.

Authors:  M C Michel
Journal:  Trends Pharmacol Sci       Date:  1991-10       Impact factor: 14.819

4.  Synthesis and biological evaluation of pNPY fragments.

Authors:  W Danho; J Triscari; G Vincent; T Nakajima; J Taylor; E T Kaiser
Journal:  Int J Pept Protein Res       Date:  1988-12

5.  Compartmentation of alpha 2-adrenergic receptors in human erythroleukemia (HEL) cells.

Authors:  R M McKernan; M J Howard; H J Motulsky; P A Insel
Journal:  Mol Pharmacol       Date:  1987-08       Impact factor: 4.436

6.  Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes.

Authors:  A Balasubramaniam; S Sheriff
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

7.  Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cells.

Authors:  H J Motulsky; M C Michel
Journal:  Clin Exp Hypertens A       Date:  1989

8.  Neuropeptide Y: complete amino acid sequence of the brain peptide.

Authors:  K Tatemoto
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

9.  Neuropeptide Y receptor in pig spleen: binding characteristics, reduction of cyclic AMP formation and calcium antagonist inhibition of vasoconstriction.

Authors:  J M Lundberg; A Hemsén; O Larsson; A Rudehill; A Saria; B B Fredholm
Journal:  Eur J Pharmacol       Date:  1988-01-05       Impact factor: 4.432

10.  C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.

Authors:  J L Krstenansky; T J Owen; M H Payne; S A Shatzer; S H Buck
Journal:  Neuropeptides       Date:  1990-11       Impact factor: 3.286

View more
  7 in total

1.  Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

Authors:  J Cortijo; V Villagrasa; C Navarrete; C Sanz; L Berto; A Michel; P A Bonnet; E J Morcillo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Analysis of receptor-G protein interactions in permeabilized cells.

Authors:  T Wieland; K Liedel; S Kaldenberg-Stasch; D Meyer zu Heringdorf; M Schmidt; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

3.  Rapid desensitization of adrenaline- and neuropeptide Y-stimulated Ca2+ mobilization in HEL-cells.

Authors:  M C Michel
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

4.  Control of cyclic AMP levels in primary cultures of human tracheal smooth muscle cells.

Authors:  I P Hall; S Widdop; P Townsend; K Daykin
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

5.  Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist; E Ratti
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

6.  Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors.

Authors:  J de Boer; A J Philpott; R G van Amsterdam; M Shahid; J Zaagsma; C D Nicholson
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

7.  Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

Authors:  J Cortijo; J Bou; J Beleta; I Cardelús; J Llenas; E Morcillo; R W Gristwood
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.